QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=2275528ED4C7BB37CFFFFE872EDAA649;jsessionid=0FB54A2CA5281D759D139018ECF3E75A;jsessionid=137833DAA552C87AEEAD330F81A19950;jsessionid=1BEE72D9639A7EFDFCAF396DD3429E24;jsessionid=7C14DE9E59063D65FE2ACA2CDD7C64DE;jsessionid=FEE7FDF9B062AE11AB5857C333A2AB40;jsessionid=CBE7605F07B3104E45F82617CD944CD6;jsessionid=95034A204DDBE3EA6DFEF95112B88F9C;jsessionid=6EE4EA4E38C535BDD806C0DD3209F8D0;jsessionid=F048189E5369069495AB6BE30FDC39CE;jsessionid=F0A13CA745EB3CFE28304306DDDA4353 (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=A8AB09FA390A3AE4E0D1D6F38BF237B8;jsessionid=51586F57457820B19218871CCD1B1B0A;jsessionid=2275528ED4C7BB37CFFFFE872EDAA649;jsessionid=0FB54A2CA5281D759D139018ECF3E75A;jsessionid=137833DAA552C87AEEAD330F81A19950;jsessionid=1BEE72D9639A7EFDFCAF396DD3429E24;jsessionid=7C14DE9E59063D65FE2ACA2CDD7C64DE;jsessionid=FEE7FDF9B062AE11AB5857C333A2AB40;jsessionid=CBE7605F07B3104E45F82617CD944CD6;jsessionid=95034A204DDBE3EA6DFEF95112B88F9C;jsessionid=6EE4EA4E38C535BDD806C0DD3209F8D0;jsessionid=F048189E5369069495AB6BE30FDC39CE;jsessionid=F0A13CA745EB3CFE28304306DDDA4353